Benzinga | Sep 17, 2020 09:20AM EDT

Tonix Pharma Will Host Live Webinar On Thursday, Sept. 24, 2020 At 10 a.m. EDT 'Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?'

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will host a live webinar on Thursday, September 24, 2020 at 10:00 a.m. ET to discuss the concept of two types of immune responses -- antibody vs. T Cell -- as well as provide an overview of the challenges of developing an effective vaccine.

Participating panelists for the event will be:

* Swati Gupta, Vice President and Head of Emerging Infectious Diseases and Scientific Strategy, IAVI. Click HERE for full bio.

* Seth Lederman, M.D., Co-Founder and CEO, Tonix Pharmaceuticals. Click HERE for full bio.

* Gokul Swaminathan, Associate Principal Scientist, Investigational Biology, Merck Research Laboratories. Click HERE for full bio.

The webinar will be held virtually and will include a Q&A session moderated by Clive Cookson, renowned Science Editor of The Financial Times. Click HERE to register and access the Zoom link for this event.

Details are as follows:

Event: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?Format: Virtual webinar followed by moderated Q&A sessionDate Thursday, September 24, 2020Time 10:00 a.m. ? 11:30 a.m. ET

A subsequent archived recording of the webinar and Q&A session will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com.